VCYT

32.92

2.46% 0.79

Handel nachbörslich: 32.92

Veracyte Inc (VCYT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$32.13

Offen:

$32.56

24-Stunden-Volumen:

833.90K

Relative Volume:

1.01

Marktkapitalisierung:

$2.62B

Einnahmen:

$517.15M

Nettoeinkommen (Verlust:

$66.35M

KGV:

40.09

EPS:

0.8212

Netto-Cashflow:

$126.63M

1W Leistung:

-1.35%

1M Leistung:

-7.97%

6M Leistung:

+1.98%

1J Leistung:

+4.47%

1-Tages-Spanne:

$32.51

$33.68

1-Wochen-Bereich:

$30.62

$34.16

52-Wochen-Spanne:

$22.61

$50.71

Veracyte Inc Stock (VCYT) Company Profile

Firmenname

Veracyte Inc

Sektor

Healthcare (1116)

Branche

Diagnostics & Research (52)

Telefon

(650) 243-6300

Adresse

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Mitarbeiter

755

Twitter

@veracyte

Nächster Verdiensttermin

2025-02-24

Neueste SEC-Einreichungen

VCYT's Discussions on Twitter

Compare VCYT vs TMO, DHR, IDXX, A, WAT

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VCYT Veracyte Inc	32.92	2.55B	517.15M	66.35M	126.63M	0.8212
TMO Thermo Fisher Scientific Inc	470.00	172.51B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	191.39	132.46B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	586.37	45.69B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	111.83	31.51B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	290.02	28.11B	3.17B	642.63M	516.49M	10.77

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-02	Fortgesetzt	Morgan Stanley	Underweight
2025-10-20	Eingeleitet	Canaccord Genuity	Hold
2025-03-20	Eingeleitet	Craig Hallum	Buy
2024-12-05	Herabstufung	Goldman	Buy → Neutral
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-10-16	Eingeleitet	UBS	Buy
2024-10-10	Eingeleitet	Guggenheim	Buy
2024-02-23	Bestätigt	Needham	Buy
2023-01-18	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-01-05	Eingeleitet	Scotiabank	Sector Outperform
2022-01-07	Eingeleitet	Stephens	Overweight
2021-11-18	Fortgesetzt	Goldman	Buy
2021-06-15	Eingeleitet	Raymond James	Outperform
2021-02-18	Fortgesetzt	Needham	Buy
2021-01-28	Eingeleitet	Truist	Buy
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2020-09-09	Eingeleitet	Morgan Stanley	Underweight
2019-07-31	Eingeleitet	Lake Street	Buy
2019-07-02	Eingeleitet	Needham	Buy
2018-11-29	Herabstufung	Janney	Buy → Neutral
2018-10-31	Hochstufung	Janney	Neutral → Buy
2017-11-07	Herabstufung	Janney	Buy → Neutral
2017-11-07	Herabstufung	Piper Jaffray	Overweight → Neutral
2017-08-31	Fortgesetzt	BTIG Research	Buy
2016-11-14	Fortgesetzt	Leerink Partners	Outperform
2015-12-18	Eingeleitet	Cantor Fitzgerald	Buy
2015-06-11	Bestätigt	Leerink Partners	Outperform
2013-11-26	Eingeleitet	William Blair	Outperform

Alle ansehen

Veracyte Inc Aktie (VCYT) Neueste Nachrichten

06:31 AM

Veracyte (VCYT) Appoints New Chief Development and Technology Of - GuruFocus

06:31 AM

06:19 AM

Veracyte names Kevin Haas as Chief Development and Technology Officer - TipRanks

06:19 AM

05:13 AM

Veracyte names Kevin Haas as chief development and technology officer - marketscreener.com

05:13 AM

05:09 AM

Veracyte Names Kevin Haas As Chief Development And Technology Officer - TradingView

05:09 AM

04:59 AM

Veracyte Appoints Kevin Haas as Chief Technology Leader - TipRanks

04:59 AM

04:26 AM

Veracyte appoints Kevin Haas as chief development officer By Investing.com - Investing.com Canada

04:26 AM

04:25 AM

Veracyte appoints Kevin Haas as chief development officer - Investing.com

04:25 AM

04:15 AM

Veracyte Names Kevin Haas as Chief Development and Technology Officer - Business Wire

04:15 AM

08:36 AM

Iron Triangle Partners LP Purchases New Position in Veracyte, Inc. $VCYT - MarketBeat

08:36 AM

06:19 AM

Fred Alger Management LLC Takes $26.35 Million Position in Veracyte, Inc. $VCYT - MarketBeat

06:19 AM

04:21 AM

Bamco Inc. NY Decreases Stake in Veracyte, Inc. $VCYT - MarketBeat

04:21 AM

Mar 15, 2026